FDA Takes Further Steps to Confront Opioid Crisis Through Risk Evaluation and Mitigation Strategy Programs
The FDA took further steps to strengthen the transmucosal immediate-release fentanyl (TIRF) REMS program with approval of modifications that which will ensure that the benefits of these drugs continue to outweigh the risks.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Drugs & Pharmacology | Fentanyl